Has the Expert Committee of the Food and Drug Administration unanimously approved Eli Lilly's new drug? Will Alzheimer's patients have new choices?
楚一帆
发表于 2024-6-11 17:23:42
222
0
0
On June 10th, Lilly's Alzheimer's disease (AD) drug Donanemab was unanimously approved by the FDA's Advisory Committee on Peripheral and Central Nervous System Drugs (PCNS).
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Has the era of AI's iPhone begun? Altman targets AI hardware with a single image to understand his billion dollar investment empire
- Don't just focus on the storm caused by the strong US dollar: Will these stocks have opportunities on a global scale?
- After Tesla's two major super factories land in Shanghai Lingang in five years, will there be a third one for vehicle and energy storage?
- Eli Lilly's new drug for Alzheimer's disease, Kisumla, has been approved by the US FDA
- The second Alzheimer's disease drug approved by the United States: Eli Lilly R&D, with an annual treatment cost of $32000
- Eli Lilly's new Alzheimer's disease drug Donanemab has been approved for pricing in Japan
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
